CAGRILINTIDE 10MG

What is Cagrilintide?

Cagrilintide (NNC0165-1875) is a highly innovative, long-acting synthetic peptide that represents a major advancement in weight management and metabolic research. It functions as a long-acting amylin analogue and a non-selective amylin receptor agonist (AMYR), while also binding to calcitonin receptors (CTR). Amylin is a hormone naturally co-secreted with insulin that regulates fullness. Cagrilintide is engineered with a specific fatty acid modification that extends its half-life, making it one of the most effective compounds available for studying multi-pathway satiety induction and homeostatic weight regulation.

Key Research Benefits & Mechanisms

• Advanced Fullness & Satiety Models: Mimics and extends the action of natural amylin, targeting the hindbrain to powerfully signal fullness, suppress appetite, and eliminate food-seeking behavior in preclinical designs.
• Delayed Gastric Emptying: Slows the rate at which food leaves the stomach, allowing researchers to study prolonged nutrient absorption models and long-term appetite reduction.
• Synergistic Metabolic Effects: Frequently researched alongside GLP-1 receptor agonists (such as Semaglutide) to explore how combining amylin pathways with incretin pathways produces a compounding, breakthrough weight loss effect.
• Suppresses Glucagon Secretion: Inhibits the inappropriate release of glucagon after nutrient intake, serving as an exceptional model for studying optimal postprandial glucose stability.
• Supports Healthy Body Composition: Focuses metabolic pathways toward significant adipose (fat) reduction while preserving lean skeletal muscle tissue during intensive weight loss trials.
• Extended Plasma Half-Life: Outlasts native amylin by days rather than minutes due to its lipid-conjugate design, allowing for steady, long-term observation of receptor binding dynamics.